Next Article in Journal
Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions
Previous Article in Journal
Understanding and Overcoming Chemoresistance in Ovarian Cancer: Emerging Role of the Endothelin Axis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 1
10.3747/co.19.945
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Major Histocompatibility Complex Class I and Tumour Immuno-Evasion: How to Fool T Cells and Natural Killer Cells at One Time

by
D. Fruci
1,
M. Benevolo
2,
L. Cifaldi
1,
S. Lorenzi
1,
E. Lo Monaco
3,
E. Tremante
3 and
P. Giacomini
3,*
1
IRCCS, Ospedale Pediatrico Bambino Gesù, Oncohaematology Department, Rome, Italy
2
Pathology Department, Regina Elena National Cancer Institute, Rome, Italy
3
Laboratory of Immunology, Regina Elena National Cancer Institute, Rome, Italy
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(1), 39-41; https://doi.org/10.3747/co.19.945
Submission received: 2 November 2011 / Revised: 4 December 2011 / Accepted: 6 January 2012 / Published: 1 February 2012

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Cytotoxic T lymphocytes (ctls) and natural killer (nk) cells lyse tumours expressing and lacking, respectively, properly conformed class i molecules of the major histocompatibility complex [mhc-i (Figure 1)] [...]

Share and Cite

MDPI and ACS Style

Fruci, D.; Benevolo, M.; Cifaldi, L.; Lorenzi, S.; Monaco, E.L.; Tremante, E.; Giacomini, P. Major Histocompatibility Complex Class I and Tumour Immuno-Evasion: How to Fool T Cells and Natural Killer Cells at One Time. Curr. Oncol. 2012, 19, 39-41. https://doi.org/10.3747/co.19.945

AMA Style

Fruci D, Benevolo M, Cifaldi L, Lorenzi S, Monaco EL, Tremante E, Giacomini P. Major Histocompatibility Complex Class I and Tumour Immuno-Evasion: How to Fool T Cells and Natural Killer Cells at One Time. Current Oncology. 2012; 19(1):39-41. https://doi.org/10.3747/co.19.945

Chicago/Turabian Style

Fruci, D., M. Benevolo, L. Cifaldi, S. Lorenzi, E. Lo Monaco, E. Tremante, and P. Giacomini. 2012. "Major Histocompatibility Complex Class I and Tumour Immuno-Evasion: How to Fool T Cells and Natural Killer Cells at One Time" Current Oncology 19, no. 1: 39-41. https://doi.org/10.3747/co.19.945

APA Style

Fruci, D., Benevolo, M., Cifaldi, L., Lorenzi, S., Monaco, E. L., Tremante, E., & Giacomini, P. (2012). Major Histocompatibility Complex Class I and Tumour Immuno-Evasion: How to Fool T Cells and Natural Killer Cells at One Time. Current Oncology, 19(1), 39-41. https://doi.org/10.3747/co.19.945

Article Metrics

Back to TopTop